Table 3.

Potential biomarkers for correlation with clinical response in clinical studies of HDACi

BiomarkerDiseaseHDACi
Tumor and/or PBMC hyperacetylation (variably by immunohistochemistry, RNA analysis, flow cytometry)AMLVorinostat (22), MGCD0103 (45, 48), panobinostat (51), entinostat (61), belinostat (59, 60)
CTCLVorinostat (19), romidepsin (35), panobinostat (55)
PTCLRomidepsin (40)
Inhibition of whole cell total HDAC activity in PBMCAMLMGCD0103 (44)
Tumor STAT1 localization and STAT3 phosphorylationCTCLVorinostat (21)
Tumor reactive oxygen species generation by gene arrayAMLVorinostat (23)
Overexpression of p21 and p53 responsive genesAMLVorinostat (24), entinostat (61)
MDR-1 gene expression and blood fetal hemoglobinCTCL and PTCLRomidepsin (35)
Plasma IL-6B-cell NHLBelinostat (60)
Plasma TARC levelHLMGCD0103 (47), vorinostat (50)
  • Abbreviations: MDR-1, multidrug resistance 1.